期刊文献+

诸脏纤化 久病久痛 皆属于络——仝小林教授从络论治脏器纤维化 被引量:16

Organ Fibrosis, chronic disease and pain all belong to collaterals disease——Professor TONG Xiaolin in the treatment of organ fibrosis focusing on collaterals disease
下载PDF
导出
摘要 脏器纤维化,其病理基础与微循环障碍密切相关。脏器纤维化可归属于中医"络病"范畴,瘀血阻络是其重要病机。仝小林教授以"络病"理论辨治脏器纤维化,提出预防及延缓纤维化的有效方药。以早期治络、全程通络为主要治则的中药干预治疗可以有效延缓纤维化的进程,提高患者生活质量。 Organ fibrosis is a refractory chronic disease caused by microcirculatory disturbance, and its pathological basis is closely related to microcirculation disorders. It can be attributed to the category of "Collaterals disease" in traditional Chinese Medicine. The main pathogenesis of the disease is the obstruction of collaterals by blood stasis. Professor TONG Xiaolin identified and treated visceral fibrosis with "Collateral disease" theory, and put forward effective prescription for preventing and delaying fibrosis. The intervention therapy of Chinese medicine, which takes the early treatment of collaterals and the whole course of collaterals as the main treatment principle, can effectively delay the process of fibrosis and improve the quality of life of the patients.
作者 王翼天 邸莎 逄冰 WANG Yitian;DI Sha;PANG Bing(Guang'anmen Hospital, China Academy of Chinese Medicine Science, Beijing 100053, China)
出处 《吉林中医药》 2018年第5期520-523,共4页 Jilin Journal of Chinese Medicine
基金 国家自然科学基金项目(81430097)
关键词 脏器纤维化 络病 仝小林 活血化瘀通络 补益气血 祛邪通络 organ fibrosis collaterals disease TONG Xiaolin activating blood resolving stasis and freeing the network vessels tonify qi and replenish blood dispel evils and free the network vessels
  • 相关文献

参考文献4

二级参考文献33

  • 1唐政,黎磊石.IgA肾炎伴新月体形成的临床和病理[J].中华肾脏病杂志,1993,9(2):80-82. 被引量:14
  • 2吕宏升,朱庆生,王军,朱锦宇,赵广跃,张大伟.全自动显微镜及图像分析系统处理免疫组化图像[J].中国体视学与图像分析,2004,9(1):37-40. 被引量:63
  • 3王吉耀.内科学[M].北京:人民卫生出版社,2008:546
  • 4RAGHU G,BROWN K K,BRADFORD W Z,et al.A placebo-controlled trail interferon gamma-1b in patients with idiopathic pulmonary fibrosis[J].N Ensl J Med,2004,350(2):125-133.
  • 5SELMAN M,KING T E,PARDO A,et al.Idiopathic pulmonary fibrosis:prevailing and evolving hypotheses about its pathogene-sis and implications for therapy[J].Ann Intern Med,2001,134 (2):136-151.
  • 6Qi W E, Chen X Met al. Transforming growth factor - 1t/con- nective tissue growth factor axis in the kidney [ J ]. The Interna- tional Journal of Biochemistry & Cell Biology ,2008,40:9 -13.
  • 7Andrew L. CCN2 : a bona fide target for anti - fibrotic drug inter- vention [ J]. Cell Commun. Signal,2011,5 : 131 - 133.
  • 8Peter B, Katarina S. Treatment targets in renal fibrosis [ J ]. Nephrol Dial Transplant ,2007,22 : 3391 - 3407.
  • 9Akira M,Chen J,Cathy l,et al. Antibody to transforming growth factor - b ameliorates tubular apoptosis in unilateral ureteral ob- struction[J]. Kidney Int. 2000,58:2301 2313.
  • 10Andrew L, Sunil K, et al. Connective tissue growth factor ( CT- GF, CCN2 ) gene regulation : a potent clinical bio - marker of fi- broproliferative diseasef [ J] Cell Commun. Signal,2009,3:89 94.

共引文献63

同被引文献254

引证文献16

二级引证文献121

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部